Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma
March 12, 2020 07:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., March 12, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company devoted to developing immune cell therapies for cancer and other diseases, today announced...
Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain
February 28, 2020 07:00 ET
|
Arcellx, Inc.
– Phase 1 trial is designed to validate novel binding domain; first step in evaluating Arcellx T cell therapy platform in the clinic – – Future trials will use Arcellx platform to direct T cell...
Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform
October 03, 2019 07:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing....